NASDAQ:CTNM • US21217B1008
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CONTINEUM THERAPEUTICS INC-A (CTNM).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-06 | Baird | Maintains | Outperform -> Outperform |
| 2026-01-08 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-11-24 | Baird | Maintains | Outperform -> Outperform |
| 2025-11-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-09-25 | Leerink Partners | Initiate | Outperform |
| 2025-08-18 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-19 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-03-13 | Jones Trading | Initiate | Buy |
| 2025-03-07 | Baird | Maintains | Outperform -> Outperform |
| 2025-01-09 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-10-22 | Baird | Initiate | Outperform |
| 2024-08-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-04-30 | RBC Capital | Initiate | Outperform |
| 2024-04-30 | Stifel | Initiate | Buy |
| 2024-04-30 | Morgan Stanley | Initiate | Overweight |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 50M | -100.00% | 1.87M | -100.00% | 13.991M | 19.427M 38.85% | 21.262M 9.45% | 93.763M 340.99% | 287.95M 207.10% | |||||
| EBITDA YoY % growth | -28.322M | -22.391M 20.94% | 16.272M 172.67% | -47.375M -411.18% | -69.374M -33.77% | -99.246M -46.52% | -136.686M -37.72% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.647M | -22.72M 20.69% | 16.077M 170.76% | -48.276M -416.56% | -65.885M -33.73% | -81.918M -20.36% | -98.506M -20.25% | -130.632M -32.61% | -160.887M -23.16% | -194.171M -20.69% | -342.086M -76.18% | -334.417M 2.24% | -149.203M 55.38% | |
| Operating Margin | N/A | N/A | 32.15% | N/A | N/A | N/A | -5,267.69% | N/A | -1,149.93% | -999.49% | -1,608.91% | -356.66% | -51.82% | |
| EPS YoY % growth | N/A | N/A | N/A | -1.95 | -2.11 55.51% | -2.24 -2.87% | -2.14 4.79% | -2.59 -21.10% | -2.86 -10.45% | -2.89 -1.07% | -3.71 -28.39% | -3.16 14.77% | -1.35 57.27% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.54 12.57% | -0.65 -4.06% | -0.53 -17.87% | -0.60 -22.12% | -0.48 11.56% | -0.49 24.11% | -0.37 30.77% | -0.37 38.64% |
| Revenue Q2Q % growth | 5.763M | N/A | N/A | N/A | N/A | |||
| EBITDA Q2Q % growth | -23.062M -27.90% | -24.284M -36.85% | -26.118M -27.88% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.116M -5.56% | -22.848M -27.63% | -18.564M 4.72% | -23.358M -75.72% | N/A | N/A | N/A | N/A |
All data in USD
13 analysts have analysed CTNM and the average price target is 20.74 USD. This implies a price increase of 59.54% is expected in the next year compared to the current price of 13.
CONTINEUM THERAPEUTICS INC-A (CTNM) will report earnings on 2026-05-12.
The consensus EPS estimate for the next earnings of CONTINEUM THERAPEUTICS INC-A (CTNM) is -0.54 USD and the consensus revenue estimate is 0 USD.
The consensus rating for CONTINEUM THERAPEUTICS INC-A (CTNM) is 86.1538 / 100 . This indicates that analysts generally have a positive outlook on the stock.